Abstract
目的探讨MicroRNA-191（miR-191）与T淋巴母细胞性白血病/淋巴瘤（T-ALL/LBL）的相关性及其作用机制。方法采用荧光实时定量PCR（qRT-PCR）法检测20例T-ALL/LBL患者肿瘤组织和20例淋巴结反应性增生（LRH）患者淋巴结组织中miR-191的表达，并分析其与临床预后的关系。构建反义miR-191慢病毒载体（LV-miR-191-KD）和阴性对照载体（LV-NC-GFP）并转染T-ALL细胞系Jurkat细胞，qRT-PCR法检测miR-191的表达水平。分别用CCK-8法和流式细胞术检测下调miR-191后的细胞活性、细胞周期和凋亡。结果T-ALL/LBL患者组miR-191表达水平明显高于LRH患者组（1.875±0.079对1.000，P=0.001），以miR-191表达量的中位数为界，将T-ALL/LBL患者分为高表达组（10例）与低表达组（10例），高表达组患者3年OS率明显低于低表达组（26%对82%，P=0.021）。转染48 h后，LV-miR-191-KD组Jurkat细胞miR-191表达水平（0.578±0.012）较LV-NC-GFP组（1.011±0.053）和未转染对照组（1.000）显著降低（P值分别为0.018和0.021），细胞凋亡比例显著升高（P值均<0.05），细胞周期阻滞于G0/G1期，并抑制从G1期向S期转化。结论miR-191在T-ALL/LBL的发生、发展过程中起促进作用，可能作为T-ALL/LBL治疗的潜在靶点。
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
